Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 435

1.

Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.

Serinet MO, Jacquemin E, Habes D, Debray D, Fabre M, Bernard O.

J Pediatr Gastroenterol Nutr. 2002 Apr;34(4):389-93.

PMID:
11930095
2.

Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.

Berney T, Delis S, Kato T, Nishida S, Mittal NK, Madariaga J, Levi D, Nery JR, Cirocco RE, Gelman B, Ruiz P, Tzakis AG.

Transplantation. 2002 Oct 15;74(7):1000-6.

PMID:
12394845
3.

Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.

Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, Hariharan S.

Clin Transplant. 2003 Oct;17(5):417-22.

PMID:
14703923
4.

Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.

Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.

Pediatr Transplant. 2004 Jun;8(3):267-72.

PMID:
15176965
5.

Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.

Verschuuren EA, Stevens SJ, van Imhoff GW, Middeldorp JM, de Boer C, Koëter G, The TH, van Der Bij W.

Transplantation. 2002 Jan 15;73(1):100-4.

PMID:
11792987
6.

Rational management of posttransplant lymphoproliferative disorder in pediatric recipients.

Praghakaran K, Wise B, Chen A, Schwarz K, Colombani P.

J Pediatr Surg. 1999 Jan;34(1):112-5; discussion 115-6.

PMID:
10022154
7.

Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.

Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehée A, Rohrlich P, Peuchmaur M, Matthieu-Boué A, Fischer A, Vilmer E.

Br J Haematol. 2001 Oct;115(1):112-8.

PMID:
11722420
8.

Early posttransplant lymphoproliferative disease in pediatric liver transplant recipients.

Roque J, Rios G, Humeres R, Volpi C, Herrera JM, Schultz M, Rios H, Rius M, Salgado C, Hepp J.

Transplant Proc. 2006 Apr;38(3):930-1.

PMID:
16647513
9.

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.

McDiarmid SV, Jordan S, Kim GS, Toyoda M, Goss JA, Vargas JH, Martín MG, Bahar R, Maxfield AL, Ament ME, Busuttil RW.

Transplantation. 1998 Dec 27;66(12):1604-11. Erratum in: Transplantation 1999 Sep 27;68(6):909. Lee GS [corrected to Kim GS].

PMID:
9884246
10.

Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease.

Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA.

Am J Transplant. 2005 Mar;5(3):566-72.

11.

Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.

Jain AB, Marcos A, Pokharna R, Shapiro R, Fontes PA, Marsh W, Mohanka R, Fung JJ.

Transplantation. 2005 Dec 27;80(12):1692-8.

PMID:
16378063
13.

Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.

Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.

Transplantation. 1997 Nov 27;64(10):1438-42.

PMID:
9392308
14.

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases.

Zompi S, Tulliez M, Conti F, Leblond V, Gaulard P, Blanche P, Durand F, Ghandi D, Dreyfus F, Louvel A, Calmus Y, Bouscary D.

J Hepatol. 2000 Mar;32(3):521-7.

PMID:
10735625
15.
16.
17.

Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.

Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J.

Transplantation. 1998 Oct 27;66(8):1047-52.

PMID:
9808490
18.
19.

Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.

Hayashida M, Ogita K, Matsuura T, Takahashi Y, Nishimoto Y, Ohga S, Hara T, Soejima Y, Taketomi A, Maehara Y, Kohashi K, Tsuneyoshi M, Taguchi T.

Pediatr Transplant. 2007 Sep;11(6):671-5.

PMID:
17663692
20.

Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.

Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B, Oertel S.

Transplantation. 2007 Apr 15;83(7):912-8.

PMID:
17460562

Supplemental Content

Support Center